Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: DRUG: Tumor infiltrating lymphocytes (TIL) LN-145
Sponsor: Yale University
Collaborators: Iovance Biotherapeutics, Inc.